One Prescription Can Rewrite the Benefits Budget, SHARx Warns
As new treatments enter the market with six-and seven-figure prices, SHARx’s Paul Pruitt says employers need to prepare for high-cost specialty-drug exposure across pharmacy and medical benefits while protecting employees’ access to care.
Many new prescriptions come with price tags that can eat up a large part of an employer’s annual healthcare forecast. For self-funded employers, those costs are changing specialty pharmacy from a benefits-management issue into a different financial risk.
